This site use cookies
This site uses cookies that help us to improve our site by providing analytics and usage information. By clicking accept or continuing to use this site you are agreeing to our cookie policy. If you do not agree, please close this notice. Learn more


Our mission is to profoundly improve the treatment of patients with retinal vascular diseases and to transform the lives of those suffering from vision loss

Exonate aims to introduce a revolutionary, game-changing eye drop for the treatment of retinal vascular diseases, including wet Age-Related Macular Degeneration (wAMD) and Diabetic Macular Oedema (DMO), by using mRNA targeted therapies.

Video courtesy of British Business Bank’s Business Finance Guide.

About Exonate

Exonate is a Cambridge and Nottingham, UK-based biotechnology company developing novel, non-invasive, small-molecule therapeutics for patients with retinal vascular diseases leading to vision loss.

Our pipeline is built around inhibition of pro-angiogenic VEGF by influencing splice patterns, for the treatment of ophthalmic conditions caused by blood vessel growth, such as Diabetic Eye Disease and wet Age-Related Macular Degeneration (wet AMD).

Developed to penetrate to the back of the eye and prevent growth of blood vessels, our treatments for retinal diseases are being developed as eye drops, eliminating the need for monthly injections into the eye, laser surgery or use of steroids, improving patient wellbeing without sacrificing potency or permeability.

There is a large unmet need for a topical therapy for diabetic retinopathy and diabetic macular oedema that can treat the conditions earlier in the disease process. Our lead asset, EXN407, has the potential to be the first topical treatment for retinal vascular diseases, including diabetic retinopathy and diabetic macular oedema. EXN407 has shown encouraging signs of efficacy, alongside meeting all endpoints, in a Phase Ib/IIa trial in diabetic patients with retinal eye disease (diabetic macular oedema).

The Company is led by a highly experienced management team, and has a strong foundation of scientific expertise, with cross-disciplinary experience in medicine and drug development.

Our History

Feb 2014

Nottingham Angels and Fusion IP make first investment in University spin-out business, Exonate

Dec 2015

Dr Chris Torrance joins the Exonate Board of Directors Prof Pete Adamson and Prof Usha Chakravarthy join the Exonate CAB

Meet our Team

Oct 2015

Exonate closes 2nd successful funding round

Nov 2016

Exonate closes 3rd successful funding round – to develop eye drops treatment for wet age-related macular degeneration (wet AMD)

John Kurek Uniseed joins the Exonate Board of Directors

Meet John Kurek

Jan 2017

Exonate turns 3! Andy Baxter joins as Head of Product Development

Meet Andy Baxter

Feb 2017

Exonate receives Wellcome Trust funding to develop eye drop treatment for wet age-related macular degeneration (wet AMD)

See our Investors

Jul 2017

Exonate is the ‘One to Watch’ in the Best Investment in Life Sciences

Nov 2017

Exonate announces the formation of ophthalmology Clinical Advisory Board (“Exonate” or the “Company”)

Meet the Team

Jan 2018

Exonate nominates compounds for clinical development

Jan 2019

Exonate raises £1.5 million during successful fourth financing round

See our Investors

Mar 2019

Exonate recognised in Top 21 companies to watch award from Cofinitive

See our Updates

Experienced and international team

Our strength is scientific expertise with cross-disciplinary experience in medicine and drug development, alongside a track record of raising capital for early stage companies. Our work is supported by highly respected Clinical and Scientific Advisory boards made up of leading international Key Opinion Leaders (KOLs) from the ophthalmology industry.

Exonate is a strong well-funded business

As an early stage biotechnology company, we are a strong, well-funded International business, supported by a highly-respected Blue-chip investors.